EUVIMEDEUVIMED entdecken
Crossref

Clinical usefulness of E4-phytohemagglutinin reactive C4-binding protein relative front value in serum for distinguishing between ovarian clear cell adenocarcinoma and endometrioma

Kayoko Shimizu, Tomotaka Sakamoto, Toshinari Ohashi, Kazuhiro Tanabe, Io Hayashi, Masae Ikeda, Mikio Mikami

Clinica Chimica Acta · 2025

DOI: 10.1016/j.cca.2025.120219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinica Chimica Acta, 2025. Verfasst von Kayoko Shimizu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Clinical Diagnostics, Fujifilm Wako Pure Chemical Corporation, Osaka, Japan. Electronic address: kayoko.kidowaki@fujifilm.com. Hauptthemen laut MEDLINE: Endometriosis, Ovarian Neoplasms, Adenocarcinoma, Clear Cell, Complement C4b-Binding Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: We identified a fully sialylated glycopeptide of the α-chain of Complement 4 binding protein (C4BP) in blood using Liquid chromatography/Mass spectrometry, which helps differentiate ovarian clear cell carcinoma (OCCC) from endometrioma (EM). We aimed to develop a blood measurement system to immunologically assess fully sialylated α-chain of C4BP, specifically E4-phytohemagglutinin-reactive C4BP (P-C4BP-Rf). MATERIALS AND METHODS: Ninety-seven serum samples were collected from healthy (HE) (n = 11), uterine fibroid (UF) patients (n = 15), EM patients (n = 32), and OCCC patients (n = 39). P-C4BP-Rf was measured using lectin affinity electrophoresis and antibody affinity blotting. CA125 and human epididymal protein 4 (HE4) levels were also measured and compared. We selected 22 EM and 24 OCCC with no significant differences in CA125 levels. Tissue factor pathway inhibitor 2 (TFPI2) and FS-C4BP were added to the analysis to distinguish OCCC from EM using five biomarkers. RESULTS: P-C4BP-Rf was significantly higher in OCCC than in HE, UF, and EM (P < 0.0001). AUC values were: CA125, 0.547; HE4, 0.850; TFPI2, 0.847; FS-C4BP, 0.715; and P-C4BP-Rf, 0.887. The combination of P-C4BP-Rf and HE4 yielded the highest AUC (0.960). CONCLUSION: P-C4BP-Rf is useful for distinguishing OCCC from EM and may be more accurate when combined with HE4.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EndometriosisOvarian NeoplasmsAdenocarcinoma, Clear CellComplement C4b-Binding ProteinHumansFemaleMiddle AgedAdultDiagnosis, DifferentialBiomarkers, Tumor

Stichwörter der Autor:innen

C4-binding proteinE4-phytohemagglutininImmunologyOvarian clear cell carcinomaSialylation

Substanzen

Complement C4b-Binding ProteinBiomarkers, Tumor

Autor:innen und Institutionen

  • Research Institute of Clinical Diagnostics, Fujifilm Wako Pure Chemical Corporation, Osaka, Japan. Electronic address: kayoko.kidowaki@fujifilm.com.
  • Research Institute of Clinical Diagnostics, Fujifilm Wako Pure Chemical Corporation, Osaka, Japan. Electronic address: tomotaka.sakamoto@fujifilm.com.
  • Research Institute of Clinical Diagnostics, Fujifilm Wako Pure Chemical Corporation, Osaka, Japan. Electronic address: toshinari.ohashi@fujifilm.com.
  • Medical Solution Segment LSI Medience Corporation, Tokyo, Japan. Electronic address: tanabe.kazuhiro@mp.medience.co.jp.
  • Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan. Electronic address: hayashiio@tokai.ac.jp.
  • Faculty of Medical Sciences, Shonan University of Medical Sciences, Kangawa, Japan; Department of Gynecology, Chigasaki Central Hospital, Kanagawa, Japan. Electronic address: ikedam@tokai.ac.jp.

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Shimizu, K., Sakamoto, T., Ohashi, T., Tanabe, K., Hayashi, I., Ikeda, M., & Mikami, M. (2025). Clinical usefulness of E4-phytohemagglutinin reactive C4-binding protein relative front value in serum for distinguishing between ovarian clear cell adenocarcinoma and endometrioma. Clinica Chimica Acta. https://doi.org/10.1016/j.cca.2025.120219

Vancouver

Shimizu K, Sakamoto T, Ohashi T, Tanabe K, Hayashi I, Ikeda M, et al. Clinical usefulness of E4-phytohemagglutinin reactive C4-binding protein relative front value in serum for distinguishing between ovarian clear cell adenocarcinoma and endometrioma. Clinica Chimica Acta. 2025. doi:10.1016/j.cca.2025.120219

BibTeX
@article{Shimizu2025,
  author = {Shimizu, Kayoko and Sakamoto, Tomotaka and Ohashi, Toshinari and Tanabe, Kazuhiro and Hayashi, Io and Ikeda, Masae and Mikami, Mikio},
  title = {Clinical usefulness of E4-phytohemagglutinin reactive C4-binding protein relative front value in serum for distinguishing between ovarian clear cell adenocarcinoma and endometrioma},
  journal = {Clinica Chimica Acta},
  year = {2025},
  doi = {10.1016/j.cca.2025.120219}
}
Kostenlos starten →